Alzamend Neuro Inc (ALZN) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Alzamend Neuro Inc
Address
3480 Peachtree Road NE
Atlanta, GA 30326
United States of America (the)
Phone
844 722 6333
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
June 15, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Stephan Jackman | Chief Executive Officer & Director | 449,832 | 1976 |
| Milton Charles Ault | Founder & Vice Chairman | 25,000 | 1970 |
| Henry C. W. Nisser | Executive Vice President, General Counsel & Director | 50,000 | 1969 |
| David J. Katzoff | Chief Financial Officer | 150,000 | 1962 |
| Kenneth S. Cragun | Senior Vice President of Finance | 0 | 1961 |
Description
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
